Literature DB >> 10917208

Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation.

M A Spear1, F Sun, D J Eling, E Gilpin, T J Kipps, E A Chiocca, M Bouvet.   

Abstract

The viral ribonucleotide reductase (rR)-defective herpes simplex type-1 (HSV-1) virus (hrR3) has been shown previously to preferentially replicate in and kill tumor cells. This selectivity is associated with tumor cell up-regulation of mammalian rR. Ionizing radiation (IR) is currently used in the therapy of many malignancies, including glioblastoma, cervical carcinoma, and pancreatic carcinoma. IR has been shown to up-regulate mammalian rR in tumor cells and appears to increase the efficacy of at least one non-rR-deleted HSV-1 strain in an in vivo tumor model. Here, we test the hypothesis that a single therapeutic radiation fraction will increase the replication and toxicity of hrR3 for malignant cell lines in vitro. PANC-1 pancreatic carcinoma, U-87 glioblastoma, and CaSki cervical carcinoma cell lines were treated with varying doses of IR and subsequently infected with hrR3 or KOS (wild-type HSV-1 strain). Cell survival was then measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay and trypan blue exclusion cytometry. At 72 hours posttreatment, irradiation with 2 Gy reduced survival from 100% to 76% in noninfected cells, from 61% to 48% in KOS-infected cells, and from 39% to 27% in hrR3-infected PANC-1 cells. As such, analysis of variance indicated that the toxicity of the two modalities was additive. Similar additivity was seen in U-87 MG and CaSki cells. Absolute survival of hrR3-infected or KOS-infected PANC-1 cells decreased as a function of time after treatment (24-72 hours) and multiplicity of infection (MOI) (0.05-5.0). However, the relative decrease in survival with the addition of IR to hrR3 or KOS in PANC-1 cells was not markedly affected by altering MOI (0.05-5.0), time (24-72 hours), radiation dose (2-20 Gy), or cell culture conditions (confluent/growth arrested). We used fluorescence-activated cell sorter analysis with the cationic lipophilic dye DiOC6 to quantify a reduction in mitochondrial membrane potential that'is associated with apoptosis. Fluorescence-activated cell sorter analysis indicated increased apoptosis in both hrR3- and IR-treated cells at 48-72 hours, with hrR3 alone producing the most induction. Viral yields from PANC-1 cells after irradiation and infection were examined. No significant differences were seen between irradiated and nonirradiated cells in viral replication, with hrR3 producing single-step titers of 3.1 +/- 0.9 x 10(5) and 4.0 +/- 1.2 x 10(5) plaque-forming units/mL in nonirradiated and irradiated cells. Thus, complementary toxicity was seen between IR and hrR3 or KOS, regardless of cell type, time, MOI, IR dose, or culture conditions, without evidence of augmented apoptosis or viral replication.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10917208     DOI: 10.1038/sj.cgt.7700208

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  9 in total

Review 1.  Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress.

Authors:  Balveen Kaur; E Antonio Chiocca; Timothy P Cripe
Journal:  Curr Pharm Biotechnol       Date:  2012-07       Impact factor: 2.837

2.  The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus.

Authors:  K Fujii; K Kurozumi; T Ichikawa; M Onishi; Y Shimazu; J Ishida; E A Chiocca; B Kaur; I Date
Journal:  Cancer Gene Ther       Date:  2013-07-05       Impact factor: 5.987

3.  Vaccinia virus-encoded ribonucleotide reductase subunits are differentially required for replication and pathogenesis.

Authors:  Don B Gammon; Branawan Gowrishankar; Sophie Duraffour; Graciela Andrei; Chris Upton; David H Evans
Journal:  PLoS Pathog       Date:  2010-07-08       Impact factor: 6.823

Review 4.  Feasibility of herpes simplex virus type 1 mutants labeled with radionuclides for tumor treatment.

Authors:  Yan-Xia Mi; Ya-Hong Long; Yun-Chun Li
Journal:  World J Gastroenterol       Date:  2008-03-07       Impact factor: 5.742

Review 5.  Novel gene therapy approaches to pancreatic cancer.

Authors:  Matthew H Katz; Michael Bouvet
Journal:  Int J Gastrointest Cancer       Date:  2003

6.  Reshaping the Immune Microenvironment by Oncolytic Herpes Simplex Virus in Murine Pancreatic Ductal Adenocarcinoma.

Authors:  Liming Zhang; Wei Wang; Ruikun Wang; Nianchao Zhang; Hang Shang; Yang Bi; Da Chen; Cuizhu Zhang; Long Li; Jie Yin; Hongkai Zhang; Youjia Cao
Journal:  Mol Ther       Date:  2020-10-30       Impact factor: 11.454

7.  Antitumor effects of IL-12 and GM-CSF co-expressed in an engineered oncolytic HSV-1.

Authors:  Kyoung-Ju Kim; Dahye Moon; So Jung Kong; Yu Seong Lee; Youngeun Yoo; Soyoung Kim; Chan Kim; Hong Jae Chon; Joo-Hang Kim; Kyung-Ju Choi
Journal:  Gene Ther       Date:  2020-11-04       Impact factor: 5.250

8.  MicroRNA-145 regulates oncolytic herpes simplex virus-1 for selective killing of human non-small cell lung cancer cells.

Authors:  Jhy-Ming Li; Kuo-Chin Kao; Li-Fu Li; Tsung-Ming Yang; Chean-Ping Wu; Yan-Ming Horng; William W G Jia; Cheng-Ta Yang
Journal:  Virol J       Date:  2013-07-22       Impact factor: 4.099

9.  The combined effects of irradiation and herpes simplex virus type 1 infection on an immortal gingival cell line.

Authors:  Aaro Turunen; Veijo Hukkanen; Michaela Nygårdas; Jarmo Kulmala; Stina Syrjänen
Journal:  Virol J       Date:  2014-07-08       Impact factor: 4.099

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.